DC
ATYR

Diametric Capital’s aTyr Pharma ATYR Stock Holding History

Diametric Capital’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,012
Closed -$188K – 492
2025
Q2 		$188K Buy
+37,012
New +$146K 0.1% 260
2025
Q1 		– Sell
-29,812
Closed -$108K – 389
2024
Q4 		$108K Buy
+29,812
New +$90.3K 0.07% 271

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Diametric Capital's ATYR Position: Q3 2025 in Review

Diametric Capital sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 37,012 shares — an estimated $188K sold.

Diametric Capital first reported a position in ATYR in Q4 2024 and held it in 2 quarters. The position peaked at $188K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

  • Diametric Capital reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
  • Diametric Capital sold 37,012 aTyr Pharma shares in Q3 2025, an estimated $188K.
  • Diametric Capital first reported a position in aTyr Pharma in Q4 2024 and held it in 2 quarters.
  • Diametric Capital's aTyr Pharma position peaked at $188K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Diametric Capital's 13F filing for Q3 2025, filed 13 Nov 2025.